U.S. Tissue Engineering Market To Witness Massive Growth By 2030

U.S. Tissue Engineering Market Summary

The U.S. tissue engineering market size was estimated at USD 8.1 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 13.4% from 2024 to 2030. The primary driver of this growth is the rising demand for advanced tissue engineering solutions that can provide effective treatment for chronic diseases while supporting the repair and regeneration of damaged tissues. In addition, the continuous progress in regenerative medicine, the rise in funding and investments directed toward developing sophisticated tissue engineering products, and the growing need for regenerative therapies are among the crucial contributors to this market’s rapid expansion. Furthermore, increasing research efforts focused on tissue repair and reconstruction, coupled with the broader acceptance of innovative cell therapies, are expected to significantly enhance future growth opportunities.

In 2023, the U.S. accounted for over 47.8% of the global tissue engineering market, underscoring its leading role in the adoption and development of these advanced medical solutions. The rising prevalence of chronic conditions such as cardiovascular disease, diabetes, and orthopedic disorders has created a strong need for tissue engineering technologies capable of repairing or replacing impaired tissues. According to a recent study by the American Health Association, approximately 133 million citizens, nearly half of the U.S. population, are affected by at least one chronic disease, including hypertension, heart disease, or arthritis. This number is projected to rise significantly, reaching 170 million by 2030. Technological innovations in 3D tissue engineering, such as the replacement of embryonic cells with stem cells, the development of organ-on-a-chip models, and the use of 3D bioprinters capable of producing in vitro implants, are expected to further propel market growth and create new opportunities for clinical applications.

Key Market Trends & Insights

• The orthopedics, musculoskeletal, and spine segment dominated the market and accounted for the largest revenue share of 59.5% in 2023. The high prevalence of musculoskeletal disorders, which impair mobility and quality of life for millions of patients, has positioned tissue engineering as a key therapeutic tool for orthopedic surgeons. Engineered tissues are increasingly being used to repair bone and cartilage damage, providing more effective and lasting treatment alternatives.
• The cardiology and vascular segment is projected to witness the fastest CAGR of 25.0% during the forecast period. The rapid growth of this segment is attributed to the urgent demand for advanced and innovative solutions in cardiac care. Tissue engineering offers the potential to develop cardiac grafts and regenerate damaged heart tissues without triggering adverse immune responses such as immunogenicity.
• The use of advanced biomaterials, including synthetic polymers such as polyglycolic acid and polylactic acid, in cardiac tissue engineering has been instrumental in driving this growth. These biomaterials enable the creation of functional and viable engineered tissues, helping to address challenges in cardiac healthcare while opening the door for new therapeutic applications. Such developments are paving the way for a future where engineered cardiac tissues can provide improved patient outcomes and support the broader adoption of regenerative medicine practices.

Order a free sample PDF of the U.S. Tissue Engineering Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 8.1 billion
• 2030 Projected Market Size: USD 19.4 billion
• CAGR (2024 - 2030): 13.4%

Key Companies & Market Share Insights

The U.S. tissue engineering market is characterized by intense competition, with numerous manufacturers taking up different initiatives for most of the market. To maintain and grow their international footprint, these market players resort to key business tactics such as launching new products, gaining approvals, making strategic acquisitions, and fostering continuous innovation. A case in point is the extension of the research collaboration between BioMed X and AbbVie in January 2023, as announced by the independent German biomedical research entity. Based in the U.S., this renewed research alliance will concentrate on immunology and tissue engineering, following an initial collaborative project on Alzheimer’s disease at the BioMed X Institute in Heidelberg, Germany.

Key Players

• Zimmer Biomet Holdings, Inc.
• AbbVie (Allergan)
• Becton Dickinson and Company
• B. Braun
• Integra LifeSciences Corporation
• Organogenesis Holdings Inc.
• Medtronic
• ACell, Inc.
• Athersys, Inc.
• Tissue Regenix Group plc
• Stryker Corporation
• RTI Surgical, Inc.
• ReproCell, Inc.
• Baxter International, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. tissue engineering market is expanding rapidly, driven by the rising prevalence of chronic diseases, technological advancements, and the growing need for regenerative medicine. With orthopedic, musculoskeletal, and spine applications holding the largest share, and cardiology emerging as the fastest-growing sector, the market is diversifying across multiple therapeutic areas. Advances in biomaterials, stem cell therapies, and 3D bioprinting are further accelerating innovation. The country’s strong investment landscape and research activities are creating favorable conditions for market growth. As demand for effective tissue regeneration rises, the U.S. is set to remain a global leader in tissue engineering solutions through 2030.